Peng Jianqing, Fumoto Shintaro, Miyamoto Hirotaka, Chen Yi, Kuroda Naotaka, Nishida Koyo
a Graduate School of Biomedical Sciences , Nagasaki University , Nagasaki , Japan.
b Department of Pharmaceutics , China Pharmaceutical University , Nanjing , PR China.
J Drug Target. 2017 Sep;25(8):704-714. doi: 10.1080/1061186X.2017.1315687. Epub 2017 May 2.
A doxorubicin (Dox) and curcumin (Cur) combination treatment regimen has been widely studied in pre-clinical research. However, the nanoparticles developed for this combination therapy require a consecutive drug loading process because of the different water-solubility of these drugs. This study provides a strategy for the "one-step" formation of nanoparticles encapsulating both Dox and Cur. We took advantage of polyacrylic acid (PAA) and calcium carbonate (CaCO) to realise a high drug entrapment efficiency (EE) and pH-sensitive drug release using a simplified preparation method. Optimisation of lipid ratios and concentrations of CaCO was conducted. Under optimal conditions, the mean diameter of PEGylated lipid/PAA/CaCO nanoparticles with encapsulated Cur and Dox (LPCCD) was less than 100 nm. An obvious pH-sensitive release of both drugs was observed, with different Dox and Cur release rates. Successful co-delivery of Cur and Dox was achieved via LPCCD on HepG2 cells. LPCCD altered the bio-distribution of Dox and Cur in vivo and decreased Dox-induced cardiotoxicity. The current investigation has developed an efficient ternary system for co-delivery of Dox and Cur to tumours, using a "one-step" formation resulting in nanoparticles possessing remarkable pH-sensitive drug release behaviour, which may be valuable for further clinical studies and eventual clinical application.
阿霉素(Dox)和姜黄素(Cur)联合治疗方案已在临床前研究中得到广泛研究。然而,由于这两种药物的水溶性不同,为这种联合疗法开发的纳米颗粒需要连续的载药过程。本研究提供了一种“一步法”制备同时包裹Dox和Cur的纳米颗粒的策略。我们利用聚丙烯酸(PAA)和碳酸钙(CaCO₃),通过简化的制备方法实现了高药物包封率(EE)和pH敏感的药物释放。对脂质比例和CaCO₃浓度进行了优化。在最佳条件下,包裹Cur和Dox的聚乙二醇化脂质/PAA/CaCO₃纳米颗粒(LPCCD)的平均直径小于100 nm。观察到两种药物均有明显的pH敏感释放,Dox和Cur的释放速率不同。通过LPCCD在HepG2细胞上成功实现了Cur和Dox的共递送。LPCCD改变了Dox和Cur在体内的生物分布,并降低了Dox诱导的心脏毒性。目前的研究开发了一种高效的三元系统,用于将Dox和Cur共递送至肿瘤,采用“一步法”形成具有显著pH敏感药物释放行为的纳米颗粒,这可能对进一步的临床研究和最终的临床应用具有重要价值。